Payment overview · 2025
General Payments
$141.50
7 reported records · 5 companies
Healthcare provider profile · identity verified
Candice Crow
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · SHREVEPORT, LA · NPI 1376142893
Verified facts
What the public records show
CMS Open Payments records show Candice Crow received $141.50 in general payments during 2025 across 7 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.96 | 27.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.48 | 25.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.38 | 17.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.59 | 16.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.09 | 12.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.50 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 325 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 224 | 76 |
| Gabapentin | Gabapentin | 201 | 46 |
| Losartan Potassium | Losartan Potassium | 170 | 52 |
| Mounjaro | Tirzepatide | 165 | 23 |
| Furosemide | Furosemide | 151 | 46 |
| Potassium Chloride | Potassium Chloride | 150 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 42 |
| Lisinopril | Lisinopril | 144 | 43 |
| Meloxicam | Meloxicam | 142 | 39 |
| Ibuprofen | Ibuprofen | 133 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 25 |
| Montelukast Sodium | Montelukast Sodium | 99 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 49 |
| Omeprazole | Omeprazole | 94 | 29 |
| Jardiance | Empagliflozin | 91 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 26 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Alendronate Sodium | Alendronate Sodium | 82 | 18 |
| Lovastatin | Lovastatin | 81 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 21 |
| Simvastatin | Simvastatin | 69 | 16 |
| Metformin Hcl | Metformin Hcl | 68 | 20 |
| Trazodone Hcl | Trazodone Hcl | 68 | 20 |
| Ozempic | Semaglutide | 60 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 12 |
| Nifedipine Er | Nifedipine | 59 | 17 |
| Carvedilol | Carvedilol | 55 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 16 |
| Allopurinol | Allopurinol | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 44 | 26 |
| Spironolactone | Spironolactone | 42 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 19 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Naproxen | Naproxen | 31 | 11 |
| Valsartan | Valsartan | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Eliquis | Apixaban | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.50 · 7 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, JARDIANCE, PREVNAR 20, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error